Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

Enhanced activation of interleukin-10, heme oxygenase-1, and AKT in C5aR2-deficient mice is associated with protection from ischemia reperfusion injury-induced inflammation and fibrosis.

Thorenz A, Derlin K, Schröder C, Dressler L, Vijayan V, Pradhan P, Immenschuh S, Jörns A, Echtermeyer F, Herzog C, Chen R, Rong S, Bräsen JH, van Kooten C, Kirsch T, Klemann C, Meier M, Klos A, Haller H, Hensen B, Gueler F.

Kidney Int. 2018 Jun 20. pii: S0085-2538(18)30282-5. doi: 10.1016/j.kint.2018.04.005. [Epub ahead of print]

PMID:
29935951
2.

Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects.

Volpi S, Bult CJ, Chisholm RL, Deverka PA, Ginsburg GS, Jacob HJ, Kasapi M, McLeod HL, Roden DM, Williams MS, Green ED, Rodriguez LL, Aronson S, Cavallari LH, Denny JC, Dressler LG, Johnson JA, Klein TE, Leeder JS, Piquette-Miller M, Perera M, Rasmussen-Torvik LJ, Rehm HL, Ritchie MD, Skaar TC, Wagle N, Weinshilboum R, Weitzel KW, Wildin R, Wilson J, Manolio TA, Relling MV.

Clin Pharmacol Ther. 2018 May;103(5):778-786. doi: 10.1002/cpt.1048. Epub 2018 Mar 30.

PMID:
29460415
3.

The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting.

Cavallari LH, Beitelshees AL, Blake KV, Dressler LG, Duarte JD, Elsey A, Eichmeyer JN, Empey PE, Franciosi JP, Hicks JK, Holmes AM, Jeng L, Lee CR, Lima JJ, Limdi NA, Modlin J, Obeng AO, Petry N, Pratt VM, Skaar TC, Tuteja S, Voora D, Wagner M, Weitzel KW, Wilke RA, Peterson JF, Johnson JA.

Clin Transl Sci. 2017 May;10(3):143-146. doi: 10.1111/cts.12456. Epub 2017 Mar 14. Review. No abstract available.

4.

Metal ions and phosphatidylinositol 4,5-bisphosphate as interacting effectors of α-type plant phospholipase D.

Dreßler L, Michel F, Thondorf I, Mansfeld J, Golbik R, Ulbrich-Hofmann R.

Phytochemistry. 2017 Jun;138:57-64. doi: 10.1016/j.phytochem.2017.02.024. Epub 2017 Mar 7.

PMID:
28283189
5.

Patient perspectives on the barriers associated with medication adherence to oral chemotherapy.

Muluneh B, Deal A, Alexander MD, Keisler MD, Markey JM, Neal JM, Bernard S, Valgus J, Dressler LG.

J Oncol Pharm Pract. 2018 Mar;24(2):98-109. doi: 10.1177/1078155216679026. Epub 2016 Nov 30.

PMID:
27895220
6.

Participation in Cancer Pharmacogenomic Studies: A Study of 8456 Patients Registered to Clinical Trials in the Cancer and Leukemia Group B (Alliance).

Dressler LG, Deal AM, Owzar K, Watson D, Donahue K, Friedman PN, Ratain MJ, McLeod HL.

J Natl Cancer Inst. 2015 Jul 9;107(10). pii: djv188. doi: 10.1093/jnci/djv188. Print 2015 Oct.

7.

Preferences for return of incidental findings from genome sequencing among women diagnosed with breast cancer at a young age.

Kaphingst KA, Ivanovich J, Biesecker BB, Dresser R, Seo J, Dressler LG, Goodfellow PJ, Goodman MS.

Clin Genet. 2016 Mar;89(3):378-84. doi: 10.1111/cge.12597. Epub 2015 May 5.

8.

Lanthanides as substitutes for calcium ions in the activation of plant α-type phospholipase D.

Dressler L, Golbik R, Ulbrich-Hofmann R.

Biol Chem. 2014 Jul;395(7-8):791-9. doi: 10.1515/hsz-2014-0112.

PMID:
24643913
9.

Cancer pharmacogenomics, adoption by oncologists and patient benefit.

Dressler LG, Deal AM, Patel J, Markey J, Riper MV, McLeod HL.

Per Med. 2014 Mar;11(2):143-153. doi: 10.2217/pme.14.1.

PMID:
29751378
10.

Genomics education for the public: perspectives of genomic researchers and ELSI advisors.

Dressler LG, Jones SS, Markey JM, Byerly KW, Roberts MC.

Genet Test Mol Biomarkers. 2014 Mar;18(3):131-40. doi: 10.1089/gtmb.2013.0366. Epub 2014 Feb 4.

12.

Fe(III)-resorcylate as a spectrophotometric probe for phospholipid-cation interactions.

Dippe M, Dressler L, Ulbrich-Hofmann R.

Anal Biochem. 2014 Jan 15;445:54-9. doi: 10.1016/j.ab.2013.10.008. Epub 2013 Oct 14.

PMID:
24135656
13.
14.

Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.

Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C, Livasy C, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, van 't Veer L, Hylton N.

J Clin Oncol. 2012 Sep 10;30(26):3242-9. doi: 10.1200/JCO.2011.39.2779. Epub 2012 May 29.

15.

Ethical aspects of participation in the database of genotypes and phenotypes of the National Center for Biotechnology Information: the Cancer and Leukemia Group B Experience.

Peppercorn J, Shapira I, Deshields T, Kroetz D, Friedman P, Spears P, Collyar DE, Shulman LN, Dressler L, Bertagnolli MM.

Cancer. 2012 Oct 15;118(20):5060-8. doi: 10.1002/cncr.27515. Epub 2012 Mar 13.

16.

IRB perspectives on the return of individual results from genomic research.

Dressler LG, Smolek S, Ponsaran R, Markey JM, Starks H, Gerson N, Lewis S, Press N, Juengst E, Wiesner GL; GRRIP Consortium.

Genet Med. 2012 Feb;14(2):215-22. doi: 10.1038/gim.2011.10. Epub 2012 Jan 5.

17.

Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).

Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, Buxton MB, Davis SE, van't Veer LJ, Hudis C, Chin K, Wolf D, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Livasy C, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, Au A, Hylton N; I-SPY 1 TRIAL Investigators.

Breast Cancer Res Treat. 2012 Apr;132(3):1049-62. doi: 10.1007/s10549-011-1895-2. Epub 2011 Dec 25.

18.

p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905).

Lara JF, Thor AD, Dressler LG, Broadwater G, Bleiweiss IJ, Edgerton S, Cowan D, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA, Hayes DF; Cancer and Leukemia Group B.

Clin Cancer Res. 2011 Aug 1;17(15):5170-8. doi: 10.1158/1078-0432.CCR-11-0484. Epub 2011 Jun 21.

19.

Ethical and practical challenges of sharing data from genome-wide association studies: the eMERGE Consortium experience.

McGuire AL, Basford M, Dressler LG, Fullerton SM, Koenig BA, Li R, McCarty CA, Ramos E, Smith ME, Somkin CP, Waudby C, Wolf WA, Clayton EW.

Genome Res. 2011 Jul;21(7):1001-7. doi: 10.1101/gr.120329.111. Epub 2011 Jun 1.

20.

Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study.

O'Brien KM, Cole SR, Tse CK, Perou CM, Carey LA, Foulkes WD, Dressler LG, Geradts J, Millikan RC.

Clin Cancer Res. 2010 Dec 15;16(24):6100-10. doi: 10.1158/1078-0432.CCR-10-1533.

21.

Confronting real time ethical, legal, and social issues in the Electronic Medical Records and Genomics (eMERGE) Consortium.

Clayton EW, Smith M, Fullerton SM, Burke W, McCarty CA, Koenig BA, McGuire AL, Beskow LM, Dressler L, Lemke AA, Ramos EM, Rodriguez LL; Consent and Community Consultation Working Group of the eMERGE Consortium.

Genet Med. 2010 Oct;12(10):616-20. doi: 10.1097/GIM.0b013e3181efdbd0. No abstract available.

22.

Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer.

Garber JE, Halabi S, Tolaney SM, Kaplan E, Archer L, Atkins JN, Edge S, Shapiro CL, Dressler L, Paskett ED, Kimmick G, Orcutt J, Scalzo A, Winer E, Levine E, Shahab N, Berliner N; Cancer and Leukemia Group B.

J Natl Cancer Inst. 2010 Jul 7;102(13):942-9. doi: 10.1093/jnci/djq211. Epub 2010 Jun 16. Erratum in: J Natl Cancer Inst. 2010 Aug 4;102(15):1210. Paskett, Electra M [corrected to Paskett, Electra D].

23.

International network of cancer genome projects.

International Cancer Genome Consortium, Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, Bernabé RR, Bhan MK, Calvo F, Eerola I, Gerhard DS, Guttmacher A, Guyer M, Hemsley FM, Jennings JL, Kerr D, Klatt P, Kolar P, Kusada J, Lane DP, Laplace F, Youyong L, Nettekoven G, Ozenberger B, Peterson J, Rao TS, Remacle J, Schafer AJ, Shibata T, Stratton MR, Vockley JG, Watanabe K, Yang H, Yuen MM, Knoppers BM, Bobrow M, Cambon-Thomsen A, Dressler LG, Dyke SO, Joly Y, Kato K, Kennedy KL, Nicolás P, Parker MJ, Rial-Sebbag E, Romeo-Casabona CM, Shaw KM, Wallace S, Wiesner GL, Zeps N, Lichter P, Biankin AV, Chabannon C, Chin L, Clément B, de Alava E, Degos F, Ferguson ML, Geary P, Hayes DN, Hudson TJ, Johns AL, Kasprzyk A, Nakagawa H, Penny R, Piris MA, Sarin R, Scarpa A, Shibata T, van de Vijver M, Futreal PA, Aburatani H, Bayés M, Botwell DD, Campbell PJ, Estivill X, Gerhard DS, Grimmond SM, Gut I, Hirst M, López-Otín C, Majumder P, Marra M, McPherson JD, Nakagawa H, Ning Z, Puente XS, Ruan Y, Shibata T, Stratton MR, Stunnenberg HG, Swerdlow H, Velculescu VE, Wilson RK, Xue HH, Yang L, Spellman PT, Bader GD, Boutros PC, Campbell PJ, Flicek P, Getz G, Guigó R, Guo G, Haussler D, Heath S, Hubbard TJ, Jiang T, Jones SM, Li Q, López-Bigas N, Luo R, Muthuswamy L, Ouellette BF, Pearson JV, Puente XS, Quesada V, Raphael BJ, Sander C, Shibata T, Speed TP, Stein LD, Stuart JM, Teague JW, Totoki Y, Tsunoda T, Valencia A, Wheeler DA, Wu H, Zhao S, Zhou G, Stein LD, Guigó R, Hubbard TJ, Joly Y, Jones SM, Kasprzyk A, Lathrop M, López-Bigas N, Ouellette BF, Spellman PT, Teague JW, Thomas G, Valencia A, Yoshida T, Kennedy KL, Axton M, Dyke SO, Futreal PA, Gerhard DS, Gunter C, Guyer M, Hudson TJ, McPherson JD, Miller LJ, Ozenberger B, Shaw KM, Kasprzyk A, Stein LD, Zhang J, Haider SA, Wang J, Yung CK, Cros A, Liang Y, Gnaneshan S, Guberman J, Hsu J, Bobrow M, Chalmers DR, Hasel KW, Joly Y, Kaan TS, Kennedy KL, Knoppers BM, Lowrance WW, Masui T, Nicolás P, Rial-Sebbag E, Rodriguez LL, Vergely C, Yoshida T, Grimmond SM, Biankin AV, Bowtell DD, Cloonan N, deFazio A, Eshleman JR, Etemadmoghadam D, Gardiner BB, Kench JG, Scarpa A, Sutherland RL, Tempero MA, Waddell NJ, Wilson PJ, McPherson JD, Gallinger S, Tsao MS, Shaw PA, Petersen GM, Mukhopadhyay D, Chin L, DePinho RA, Thayer S, Muthuswamy L, Shazand K, Beck T, Sam M, Timms L, Ballin V, Lu Y, Ji J, Zhang X, Chen F, Hu X, Zhou G, Yang Q, Tian G, Zhang L, Xing X, Li X, Zhu Z, Yu Y, Yu J, Yang H, Lathrop M, Tost J, Brennan P, Holcatova I, Zaridze D, Brazma A, Egevard L, Prokhortchouk E, Banks RE, Uhlén M, Cambon-Thomsen A, Viksna J, Ponten F, Skryabin K, Stratton MR, Futreal PA, Birney E, Borg A, Børresen-Dale AL, Caldas C, Foekens JA, Martin S, Reis-Filho JS, Richardson AL, Sotiriou C, Stunnenberg HG, Thoms G, van de Vijver M, van't Veer L, Calvo F, Birnbaum D, Blanche H, Boucher P, Boyault S, Chabannon C, Gut I, Masson-Jacquemier JD, Lathrop M, Pauporté I, Pivot X, Vincent-Salomon A, Tabone E, Theillet C, Thomas G, Tost J, Treilleux I, Calvo F, Bioulac-Sage P, Clément B, Decaens T, Degos F, Franco D, Gut I, Gut M, Heath S, Lathrop M, Samuel D, Thomas G, Zucman-Rossi J, Lichter P, Eils R, Brors B, Korbel JO, Korshunov A, Landgraf P, Lehrach H, Pfister S, Radlwimmer B, Reifenberger G, Taylor MD, von Kalle C, Majumder PP, Sarin R, Rao TS, Bhan MK, Scarpa A, Pederzoli P, Lawlor RA, Delledonne M, Bardelli A, Biankin AV, Grimmond SM, Gress T, Klimstra D, Zamboni G, Shibata T, Nakamura Y, Nakagawa H, Kusada J, Tsunoda T, Miyano S, Aburatani H, Kato K, Fujimoto A, Yoshida T, Campo E, López-Otín C, Estivill X, Guigó R, de Sanjosé S, Piris MA, Montserrat E, González-Díaz M, Puente XS, Jares P, Valencia A, Himmelbauer H, Quesada V, Bea S, Stratton MR, Futreal PA, Campbell PJ, Vincent-Salomon A, Richardson AL, Reis-Filho JS, van de Vijver M, Thomas G, Masson-Jacquemier JD, Aparicio S, Borg A, Børresen-Dale AL, Caldas C, Foekens JA, Stunnenberg HG, van't Veer L, Easton DF, Spellman PT, Martin S, Barker AD, Chin L, Collins FS, Compton CC, Ferguson ML, Gerhard DS, Getz G, Gunter C, Guttmacher A, Guyer M, Hayes DN, Lander ES, Ozenberger B, Penny R, Peterson J, Sander C, Shaw KM, Speed TP, Spellman PT, Vockley JG, Wheeler DA, Wilson RK, Hudson TJ, Chin L, Knoppers BM, Lander ES, Lichter P, Stein LD, Stratton MR, Anderson W, Barker AD, Bell C, Bobrow M, Burke W, Collins FS, Compton CC, DePinho RA, Easton DF, Futreal PA, Gerhard DS, Green AR, Guyer M, Hamilton SR, Hubbard TJ, Kallioniemi OP, Kennedy KL, Ley TJ, Liu ET, Lu Y, Majumder P, Marra M, Ozenberger B, Peterson J, Schafer AJ, Spellman PT, Stunnenberg HG, Wainwright BJ, Wilson RK, Yang H.

Nature. 2010 Apr 15;464(7291):993-8. doi: 10.1038/nature08987. Erratum in: Nature. 2010 Jun 17;465(7300):966. Himmelbaue, Heinz [corrected to Himmelbauer, Heinz]; Gardiner, Brooke A [corrected to Gardiner, Brooke B]; Cross, Anthony [corrected to Cros, Anthony].

24.

Institutional profile. UNC Institute for Pharmacogenomics and Individualized Therapy: interdisciplinary research for individual care.

Rakhra-Burris TK, Auman JT, Deverka P, Dressler LG, Evans JP, Goldberg RM, Havener TM, Hoskins JM, Jonas DE, Long KM, Motsinger-Reif AA, Irvin WJ, Richards KL, Roederer MW, Valgus JM, Riper Mv, Vernon JA, Zamboni WC, Wagner MJ, Walko CM, Weck KE, Wiltshire T, McLeod HL.

Pharmacogenomics. 2010 Jan;11(1):13-21. doi: 10.2217/pgs.09.167.

25.

How will GINA influence participation in pharmacogenomics research and clinical testing?

Dressler LG, Terry SF.

Clin Pharmacol Ther. 2009 Nov;86(5):472-5. doi: 10.1038/clpt.2009.146.

PMID:
19844223
26.

Disclosure of research results from cancer genomic studies: state of the science.

Dressler LG.

Clin Cancer Res. 2009 Jul 1;15(13):4270-6. doi: 10.1158/1078-0432.CCR-08-3067. Epub 2009 Jun 23. Review.

27.

Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013.

Harris LN, Broadwater G, Abu-Khalaf M, Cowan D, Thor AD, Budman D, Cirrincione CT, Berry DA, Winer EP, Hudis CA, Hayes DF, Friedman P, Ellis M, Dressler L.

J Clin Oncol. 2009 Jul 20;27(21):3430-6. doi: 10.1200/JCO.2008.18.4085. Epub 2009 May 26.

28.

Adjuvant chemotherapy in older women with early-stage breast cancer.

Muss HB, Berry DA, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, Partridge AH, Dressler LG, Cohen HJ, Becker HP, Kartcheske PA, Wheeler JD, Perez EA, Wolff AC, Gralow JR, Burstein HJ, Mahmood AA, Magrinat G, Parker BA, Hart RD, Grenier D, Norton L, Hudis CA, Winer EP; CALGB Investigators.

N Engl J Med. 2009 May 14;360(20):2055-65. doi: 10.1056/NEJMoa0810266. Erratum in: N Engl J Med. 2009 Oct 22;361(17):1714. Magrinat, Gutav [corrected to Magrinat, Gustav].

29.

Handling, storage, and preparation of human tissues.

Dressler LG, Visscher D.

Curr Protoc Cytom. 2001 May;Chapter 5:Unit 5.2. doi: 10.1002/0471142956.cy0502s01.

PMID:
18770712
30.

Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B.

DiGiovanna MP, Stern DF, Edgerton S, Broadwater G, Dressler LG, Budman DR, Henderson IC, Norton L, Liu ET, Muss HB, Berry DA, Hayes DF, Thor AD.

J Clin Oncol. 2008 May 10;26(14):2364-72. doi: 10.1200/JCO.2007.13.6580. Epub 2008 Apr 7.

PMID:
18390970
31.

HER2 and response to paclitaxel in node-positive breast cancer.

Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA; Cancer and Leukemia Group B (CALGB) Investigators.

N Engl J Med. 2007 Oct 11;357(15):1496-506.

32.

Epidemiology of basal-like breast cancer.

Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, Smith LV, Labbok MH, Geradts J, Bensen JT, Jackson S, Nyante S, Livasy C, Carey L, Earp HS, Perou CM.

Breast Cancer Res Treat. 2008 May;109(1):123-39. Epub 2007 Jun 20. Erratum in: Breast Cancer Res Treat. 2008 May;109(1):141. Dressler, Lynn G [added].

33.

Biospecimen "ownership": counterpoint.

Dressler LG.

Cancer Epidemiol Biomarkers Prev. 2007 Feb;16(2):190-1. No abstract available.

34.

Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342.

Harris LN, Broadwater G, Lin NU, Miron A, Schnitt SJ, Cowan D, Lara J, Bleiweiss I, Berry D, Ellis M, Hayes DF, Winer EP, Dressler L.

Breast Cancer Res. 2006;8(6):R66.

35.

Thresholds and boundaries in the disclosure of individual genetic research results.

Dressler LG, Juengst ET.

Am J Bioeth. 2006 Nov-Dec;6(6):18-20; author reply W10-2. No abstract available.

PMID:
17085396
36.
37.

Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide.

Kelly H, Kimmick G, Dees EC, Collichio F, Gatti L, Sawyer L, Ivanova A, Dressler L, Graham ML, Carey LA.

Clin Breast Cancer. 2006 Aug;7(3):237-43.

PMID:
16942640
38.

Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806.

Rincon M, Broadwater G, Harris L, Crocker A, Weaver D, Dressler L, Berry D, Sutton L, Michaelson R, Messino M, Kirshner J, Fleming G, Winer E, Hudis C, Appel S, Norton L, Muss H; Cancer and Leukemia Group B.

Breast Cancer Res Treat. 2006 Dec;100(3):301-8. Epub 2006 Jun 14.

PMID:
16773437
39.

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.

Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC.

JAMA. 2006 Jun 7;295(21):2492-502.

PMID:
16757721
40.

The molecular portraits of breast tumors are conserved across microarray platforms.

Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, Nobel A, Parker J, Ewend MG, Sawyer LR, Wu J, Liu Y, Nanda R, Tretiakova M, Ruiz Orrico A, Dreher D, Palazzo JP, Perreard L, Nelson E, Mone M, Hansen H, Mullins M, Quackenbush JF, Ellis MJ, Olopade OI, Bernard PS, Perou CM.

BMC Genomics. 2006 Apr 27;7:96.

41.

Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.

Dressler LG, Berry DA, Broadwater G, Cowan D, Cox K, Griffin S, Miller A, Tse J, Novotny D, Persons DL, Barcos M, Henderson IC, Liu ET, Thor A, Budman D, Muss H, Norton L, Hayes DF.

J Clin Oncol. 2005 Jul 1;23(19):4287-97.

PMID:
15994142
42.

High focal adhesion kinase expression in invasive breast carcinomas is associated with an aggressive phenotype.

Lark AL, Livasy CA, Dressler L, Moore DT, Millikan RC, Geradts J, Iacocca M, Cowan D, Little D, Craven RJ, Cance W.

Mod Pathol. 2005 Oct;18(10):1289-94.

43.

HER2 testing: laboratory, technical and clinical considerations.

Dressler LG, Thor AD.

Breast Dis. 2000;11:77-87.

PMID:
15687594
45.

Upregulation of focal adhesion kinase (FAK) expression in ductal carcinoma in situ (DCIS) is an early event in breast tumorigenesis.

Lightfoot HM Jr, Lark A, Livasy CA, Moore DT, Cowan D, Dressler L, Craven RJ, Cance WG.

Breast Cancer Res Treat. 2004 Nov;88(2):109-16.

PMID:
15564794
46.

Mutation of GATA3 in human breast tumors.

Usary J, Llaca V, Karaca G, Presswala S, Karaca M, He X, Langerød A, Kåresen R, Oh DS, Dressler LG, Lønning PE, Strausberg RL, Chanock S, Børresen-Dale AL, Perou CM.

Oncogene. 2004 Oct 7;23(46):7669-78.

PMID:
15361840
47.

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.

Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM.

Clin Cancer Res. 2004 Aug 15;10(16):5367-74.

48.

Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression.

Chung CH, Parker JS, Karaca G, Wu J, Funkhouser WK, Moore D, Butterfoss D, Xiang D, Zanation A, Yin X, Shockley WW, Weissler MC, Dressler LG, Shores CG, Yarbrough WG, Perou CM.

Cancer Cell. 2004 May;5(5):489-500.

49.

Reproductive factors in relation to breast cancer characterized by p53 protein expression (United States).

Furberg H, Millikan RC, Geradts J, Gammon MD, Dressler LG, Ambrosone CB, Newman B.

Cancer Causes Control. 2003 Sep;14(7):609-18.

PMID:
14575358
50.

HER2 codon 655 polymorphism and risk of breast cancer in African Americans and whites.

Millikan R, Eaton A, Worley K, Biscocho L, Hodgson E, Huang WY, Geradts J, Iacocca M, Cowan D, Conway K, Dressler L.

Breast Cancer Res Treat. 2003 Jun;79(3):355-64.

PMID:
12846420

Supplemental Content

Loading ...
Support Center